• Use of patented combination of two drugs (an antidepressant and antipsychotic drug) for the dis-aggregation of toxic oligomeric proteins & other possible symptoms associated with Alzheimer’s disease (AD)
• The drug action is through dis-aggregation of previously formed toxic oligomers of amyloid proteins
• Expansion of a commercial formulation from a patient prospective as a combined single tablet, capsule or suspension aligned to the clinical program.
• Other potential indications include ‘brain fog’ associated with long COVID, post traumatic stress disorder
Commencing Phase 1b/2a clinical trials Q1 2022